Rezultati pilot studije vesnske angioplastike u oboljelih od MS

Prenosim iz europskog časopisa za vaskularnu i endovaskularnu kirurgiju

Link na izvornik članka

Article in Press

Venous Angioplasty in Patients with Multiple Sclerosis: Results of a Pilot Study

Dno obrasca

· P. Zamboni

Affiliations

oVascular Diseases Centre, University of Ferrara, C.so Giovecca 203, 44100 Ferrara, Italy

o Corresponding author. Tel.: +39 0532236524; fax: +39 0532237443.

· R. Galeotti

Affiliations

oInterventional Radiology Unit, University of Ferrara, Ferrara, Italy

· B. Weinstock-Guttman

Affiliations

oThe Jacobs Neurological Institute, University at Buffalo, Buffalo, NY, USA

· C. Kennedy

Affiliations

oBuffalo Neuroimaging Analysis Center, University at Buffalo, NY, USA

· F. Salvi

Affiliations

oBellaria Neurosciences, Bologna, Italy

· R. Zivadinov

Affiliations

oThe Jacobs Neurological Institute, University at Buffalo, Buffalo, NY, USA

oBuffalo Neuroimaging Analysis Center, University at Buffalo, NY, USA

published online 12 August 2011.

Corrected Proof

· Abstract

· Full Text

· PDF

· Images

· References

Abstract

Objectives

Chronic cerebrospinal venous insufficiency (CCSVI) is associated with multiple sclerosis (MS). The objective of the study was to see if percutaneous transluminal angioplasty (PTA) of duplex-detected lesions, of the internal jugular and/or azygous veins, was safe, burdened by a significant restenosis rate, and whether there was any evidence that treatment reduced MS disease activity.

Design: This was a case-control study.

Materials: We studied 15 patients with relapsing–remitting MS and duplex-detected CCSVI.

Methods

Eight patients had PTA in addition to medical therapy (immediate treatment group (ITG)), whereas seven had treatment with PTA after 6 months of medical therapy alone (delayed treatment group (DTG)).

Results

No adverse events occurred. At 1 year, there was a restenosis rate of 27%. Overall, PTA was followed by a significant improvement in functional score compared with baseline (p < 0.02). The annualised relapse rate was 0.12% in the ITG compared with 0.66% in the DTG (p = NS). Magnetic resonance imaging (MRI) blindly demonstrates a trend for fewer T2 lesions in the ITG (p = 0.081), corresponding to a 10% decrease in the ITG compared with a 23% increase in the DTG over the first 6 months of the study.

Conclusions

This study further confirms the safety of PTA treatment in patients with CCSVI associated with MS. The results, despite the significant rate of restenosis, are encouraging and warrant a larger multicentre double-blinded, randomised study.